00:36:50 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriMedicinteknik
Curasight är verksamma inom läkemedelsbranschen. Bolaget är specialiserade inom utveckling av teknologiska produkter. Produktportföljen är bred och fokuserar i stor grad utveckling av produkter inom området Positron Emissions Tomography (PET). Verksamheten drivs med störst närvaro inom Skandinavien. Curasight har sitt huvudkontor i Köpenhamn.

Kalender

2023-11-24 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-03-30 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-04-27 Årsstämma 2022
2022-03-25 Ordinarie utdelning CURAS 0.00 DKK
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-06-01 Extra Bolagsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-03-26 Ordinarie utdelning CURAS 0.00 DKK
2021-03-25 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-11-30 Kvartalsrapport 2020-Q3
2021-08-24 07:00:00

Curasight A/S ("Curasight" or the "Company") hereby publishes the interim report for the period January 1 - June 30, 2021. The interim report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

Curasight's CEO Ulrich Krasilnikoff comments:

"During the quarter we successfully reported positive outcome of the biodistribution study in glioblastoma with uTREAT[®], which constitutes a green light to proceed into further testing. Curasight's uTREAT[®]-technology has previously shown promising results in completed preclinical studies in prostate and colorectal cancer. When complete data from the ongoing preclinical studies are available, they will serve as the first proof that our therapeutic technology is working. We look forward to continuing the study and reporting its results on a continuous basis.

Due to the encouraging results from the finalized clinical phase-II study in Prostate Cancer, Curasight will look into how to accelerate the product development and testing within Prostate Cancer, as we follow the plan but at a lower cost level than first anticipated. This means that Curasight is looking into how to further unfold the potential of uTRACE[®] for diagnosing and uTREAT[®] targeted radionuclide therapy in other cancer types where uPAR is also expressed."

2

Q2 (2021-04-01 - 2021-06-30)
  • Net sales amounted to 0 (0) DKK
  • Operating profit/loss amounted to -404,869 (-152,386) DKK
  • Profit/loss before taxes amounted to -1,079,213 (-315,299) DKK
  • Profit/loss for the year amounted to -841,783 (-245,919) DKK
  • Total assets amounted to 60,860,495 (22,186,681) DKK
  • Equity ratio amounted to 94.4 (79.2)
  • Earnings per share amounted to -0.05 (-0.02)
Q1-Q2 (2021-01-01 - 2021-06-30)
  • Net sales amounted to 0 (0) DKK
  • Operating profit/loss amounted to -771,962 (-186,810) DKK
  • Profit/loss before taxes amounted to -2,076,728 (-563,364) DKK
  • Profit/loss for the year amounted to -1,619,848 (-439,424) DKK
  • Total assets amounted to 60,860,495 (22,186,681) DKK
  • Equity ratio amounted to 94.4 (79.2)
  • Earnings per share amounted to -0.09 (-0.03)

Highlights during the second quarter

[]
  • On April 9, Curasight's CEO Ulrich Krasilnikoff and CSO professor Andreas
Kjær presented the Company and its future plans, at the Nordnet Live platform.
  • On May 17, Curasight was awarded Best IPO in 2020 by the independent IPO
Guide.
  • On June 1, Curasight held an Extraordinary General Meeting where Dr.
Kirsten Drejer was elected as new member of the board of directors.
  • On June 18, Curasight announced that SEB will initiate commissioned

research, meaning that SEB will continuously monitor and analyze Curasight's
operations, products, markets, and competitors.

  • On June 24, Curasight reported positive biodistribution data of uTREAT[®]
in glioblastoma, which provides "green light" to proceed with the next steps
of development and testing.